Advertisement
Singapore markets close in 39 minutes
  • Straits Times Index

    3,192.48
    +37.79 (+1.20%)
     
  • Nikkei

    38,079.70
    +117.90 (+0.31%)
     
  • Hang Seng

    16,410.47
    +158.63 (+0.98%)
     
  • FTSE 100

    7,897.90
    +49.91 (+0.64%)
     
  • Bitcoin USD

    60,961.24
    -2,485.56 (-3.92%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     
  • Dow

    37,753.31
    -45.66 (-0.12%)
     
  • Nasdaq

    15,683.37
    -181.88 (-1.15%)
     
  • Gold

    2,394.50
    +6.10 (+0.26%)
     
  • Crude Oil

    82.04
    -0.65 (-0.79%)
     
  • 10-Yr Bond

    4.5850
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,545.80
    +5.38 (+0.35%)
     
  • Jakarta Composite Index

    7,172.81
    +41.97 (+0.59%)
     
  • PSE Index

    6,523.19
    +73.15 (+1.13%)
     

Five Below to Gain From Focus on Pre-Teen Despite Soft Margin

Five Below, Inc. FIVE is benefiting from merchandise assortment, focus on pre-teen customers, enhancement of digital and e-commerce channels, and pricing strategy. Moreover, healthy performance of new outlets and decent comparable sales (comps) run are aiding its performance.

Notably, shares of this Zacks Rank #3 (Hold) company have rallied 27.2% year to date against the industry’s decline of 0.2%.

 


A Brief Introspection

Five Below is trying to attract shoppers, especially teens and pre-teens, to expand the customer base. Further, the company remains focused on product innovations and refinement on ever-changing trends. These apart, its pricing strategy enables it to cater to demographic shoppers alongside resonating with value-seeking customers.

Moving ahead, the company is working toward enhancing customer experience, with refresh store format, remodeling programs and Ten Below test. It is also on track to improve the supply chain and deliver better WOW products. Further, the company is making efforts to achieve efficient cost structure, solid average net sales per store, supply-chain initiatives and economies of scale.

Buoyed by such well-chalked efforts, the company delivered a decent performance in the second quarter of fiscal 2019, wherein the top and bottom lines improved on a year-over-year basis. Moreover, Five Below registered the 11th successive quarter of comparable sales growth. Management now anticipates comps to grow 3% in fiscal 2019 and 2-3% in the third quarter. Net sales are projected to be $1,872-$1,892 million, whereas it reported $1,559.6 million in the last year.

However, stiff competition from brick-&-mortar stores and e-retailers, and operating margin deleverage, owing to higher SG&A expenses, cannot be ignored. After declining 160 basis points in the first quarter of fiscal 2019, operating margin contracted roughly 10 basis points to 8.6% in the second quarter. The company now envisions operating margin to decline about 175 basis points in the third quarter and deleverage slightly in fiscal 2019.

Management expects operating margin to remain under pressure in the fiscal third quarter due to SG&A expense deleverage, owing to depreciation expenses associated with the opening of new Southeast distribution center and adoption of the new lease accounting standard as well as a shift in merchandise costs from the second quarter to the third.

All said, we hope that Five Below’s endeavors will be able to address these challenges and help sustain momentum.

3 Better-Ranked Stocks to Watch

Regis Corporation RGS has a long-term earnings growth rate of 7.5%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Hibbett Sports, Inc HIBB has a long-term earnings growth rate of 10.9% and a Zacks Rank #2 (Buy).

Dick’s Sporting Goods DKS has a long-term earnings growth rate of 5.6% and a Zacks Rank #2 at present.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regis Corporation (RGS) : Free Stock Analysis Report
 
DICK'S Sporting Goods, Inc. (DKS) : Free Stock Analysis Report
 
Hibbett Sports, Inc. (HIBB) : Free Stock Analysis Report
 
Five Below, Inc. (FIVE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research